Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8836
|
pubmed:dateCreated |
1993-1-27
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0140-6736
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
2
|
pubmed:volume |
341
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
63
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8093319-Debrisoquin,
pubmed-meshheading:8093319-Female,
pubmed-meshheading:8093319-Humans,
pubmed-meshheading:8093319-Hydroxylation,
pubmed-meshheading:8093319-Metabolic Diseases,
pubmed-meshheading:8093319-Neurotic Disorders,
pubmed-meshheading:8093319-Polymorphism, Restriction Fragment Length
|
pubmed:year |
1993
|
pubmed:articleTitle |
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.
|
pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't
|